Atea Pharmaceuticals (AVIR) Retained Earnings (2019 - 2026)
Atea Pharmaceuticals (AVIR) recorded quarterly Retained Earnings of -$97000.0 in Q1 2026, up 99.98% quarter-over-quarter from -$522.6 million in Q4 2025, and up 99.98% on a YoY basis from -$48505.9 in Q1 2025.
Atea Pharmaceuticals (AVIR) Retained Earnings (2019 - 2026) Analysis & Trends
Atea Pharmaceuticals' Retained Earnings history runs 8 years deep, the most recent figure standing at -$97000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.98% year-over-year to -$97000.0; the TTM figure through Mar 2026 stood at -$97000.0 (up 99.98% YoY), while the FY2025 annual figure was -$522.6 million, down 43.48% from the prior year.
- Retained Earnings was -$97000.0 for Q1 2026 at Atea Pharmaceuticals, up from -$522.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $14.0 million in Q1 2022 to a low of -$522.6 million in Q4 2025.
- Historically, Retained Earnings has averaged -$110.9 million across 5 years, with a median of -$17.4 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings jumped 140.51% in 2022, then tumbled 220061.33% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$684000.0 in 2022, then sank by 28530.85% to -$195.8 million in 2023, then plunged by 85.98% to -$364.2 million in 2024, then plunged by 43.48% to -$522.6 million in 2025, then jumped by 99.98% to -$97000.0 in 2026.
- The last three Retained Earnings figures came in at -$97000.0 (Q1 2026), -$522.6 million (Q4 2025), and $238000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -838.07 Mn |
| 10 | Atea Pharmaceuticals | 347.28 Mn | 347.28 Mn | - | -97,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97,000.00 |
| Dec 31, 2025 | -522.57 Mn |
| Sep 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | -398.49 Mn |
| Dec 31, 2024 | -364.22 Mn |
| Sep 30, 2024 | 641,000.00 |
| Jun 30, 2024 | -280,000.00 |
| Mar 31, 2024 | -181,000.00 |
| Dec 31, 2023 | -195.84 Mn |
| Sep 30, 2023 | -156.67 Mn |
| Jun 30, 2023 | -123.53 Mn |
| Mar 31, 2023 | -95.35 Mn |
| Dec 31, 2022 | -684,000.00 |
| Sep 30, 2022 | -25.45 Mn |
| Jun 30, 2022 | -17.38 Mn |
| Mar 31, 2022 | 13.95 Mn |
| Dec 31, 2021 | 56.03 Mn |
| Sep 30, 2021 | -61.10 Mn |
| Jun 30, 2021 | -32.91 Mn |